Stockscreener 앱 받기
1.92
1.03%
-0.02
시간 외 거래:
1.91
-0.01
-0.52%
전일 마감가:
$1.94
열려 있는:
$1.94
하루 거래량:
134.80K
Relative Volume:
0.32
시가총액:
$15.34M
수익:
$2.90M
순이익/손실:
$87.91M
주가수익비율:
0.123
EPS:
15.6103
순현금흐름:
$-26.93M
1주 성능:
+11.63%
1개월 성능:
+51.18%
6개월 성능:
+17.79%
1년 성능:
-72.13%
1일 변동 폭
$1.8601
$2.08
1주일 범위
$1.79
$2.31
52주 변동 폭
$0.97
$7.49
Traws Pharma Inc Stock (TRAW) Company Profile
명칭
Traws Pharma Inc
전화
267-759-3680
주소
12 PENNS TRAIL, NEWTOWN
Compare TRAW vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TRAW
Traws Pharma Inc
|
1.92 | 15.50M | 2.90M | 87.91M | -26.93M | 15.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Traws Pharma Inc Stock (TRAW) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-03 | 개시 | H.C. Wainwright | Buy |
| 2022-03-01 | 개시 | Ladenburg Thalmann | Buy |
| 2021-05-18 | 개시 | Guggenheim | Buy |
| 2018-03-01 | 재확인 | H.C. Wainwright | Buy |
| 2018-01-17 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2017-10-09 | 개시 | H.C. Wainwright | Buy |
| 2017-04-27 | 개시 | Laidlaw | Buy |
| 2015-07-01 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2015-05-05 | 개시 | H.C. Wainwright | Buy |
모두보기
Traws Pharma Inc 주식(TRAW)의 최신 뉴스
Aug EndMonth: Will RSVR outperform tech stocks2025 Key Lessons & Safe Swing Trade Setups - baoquankhu1.vn
Published on: 2026-02-03 21:55:07 - baoquankhu1.vn
Experimental COVID Pill Shows Edge Over Paxlovid as Traws Hits Key Milestones - MyChesCo
LADENBURG THALM/SH SH Upgrades Traws Pharma (NASDAQ:TRAW) to Strong-Buy - Defense World
TRAW stock slides in volatile session – what’s the latest on its phase 2 trial for COVID-19 treatment? - MSN
Traws completes enrollment in phase 2 COVID-19 drug study By Investing.com - Investing.com Canada
Traws Pharma stock soars after completing COVID-19 treatment study By Investing.com - Investing.com South Africa
Traws Pharma stock soars after completing COVID-19 treatment study - Investing.com
TRAW Stock Slides In Volatile Session – What’s The Latest On Its Phase 2 Trial For COVID-19 Treatment? - Stocktwits
Traws Pharma (TRAW) Completes Enrollment in Phase 2 COVID-19 Stu - GuruFocus
Traws Pharma Completes Phase 2 Enrollment for COVID Candidate - TipRanks
Traws completes enrollment in phase 2 COVID-19 drug study - Investing.com
COVID drug tested in Paxlovid-ineligible patients as monthly flu pill advances - stocktitan.net
Traws targets stockpile nod as COVID drug outperforms Paxlovid in trial - MSN
Wall Street Recap: Can Traws Pharma Inc outperform under higher oil prices2025 Trade Ideas & Safe Capital Growth Stock Tips - baoquankhu1.vn
Traws Pharma’s TRX-100 Phase 1 Completion: A Quiet but Key Milestone for Investors - TipRanks
Traws Targets Stockpile Nod as COVID Drug Outperforms Paxlovid in Trial - MyChesCo
Can Traws Pharma Inc. grow without dilutionOptions Play & Advanced Swing Trade Entry Alerts - bollywoodhelpline.com
Published on: 2026-01-17 06:20:37 - baoquankhu1.vn
Traws Pharma files IND for influenza treatment, updates COVID drug trial - Investing.com Nigeria
Breakout Zone: How Traws Pharma Inc stock compares to market leadersPrice Action & Risk Controlled Swing Alerts - Bộ Nội Vụ
Traws Pharma files IND for influenza treatment, updates COVID drug trial By Investing.com - Investing.com India
Traws Pharma advances flu and COVID-19 antiviral pipeline - TipRanks
Traws Pharma Files IND for Tivoxavir Marboxil and Updates Ratutrelvir Study - TradingView
Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients - GlobeNewswire
Published on: 2026-01-11 07:18:09 - ulpravda.ru
New COVID pill shows promise against Paxlovid in early head-to-head trial - MSN
Fed Meeting: Is Traws Pharma Inc. stock a buy before product launches2025 Market WrapUp & Weekly Market Pulse Updates - Улправда
How resilient is Traws Pharma Inc. stock in market downturnsTrade Exit Report & Short-Term Trading Alerts - Улправда
Why Traws Pharma Inc. stock remains on watchlists2025 Market Outlook & Consistent Profit Trade Alerts - ulpravda.ru
Is Traws Pharma Inc. stock cheap at current valuationMarket Activity Report & Community Trade Idea Sharing - Улправда
How Traws Pharma Inc. stock compares to industry benchmarksPortfolio Risk Report & High Accuracy Trade Signal Alerts - Улправда
Traws Pharma, Inc. (NASDAQ:TRAW) Q2 2025 Earnings Call Transcript - MSN
Comparing Miravant Medical Technologies (OTCMKTS:MRVT) and Traws Pharma (NASDAQ:TRAW) - Defense World
Traws Pharma Pushes Ahead on COVID and Flu Antivirals as Costs Fall and Pipeline Advances - MSN
Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors - Moscow-Pullman Daily News
Traws Pharma (NASDAQ:TRAW) Shares Down 3.5% – Time to Sell? - Defense World
How Traws Pharma Inc. stock compares to growth peersTechnical Resistance Breaks & Fast Growing Capital Gains - bollywoodhelpline.com
CLARKE TRAFFORD Insider Trades - Nasdaq
Why Traws Pharma Inc. (0T20) stock stays on top picksAnalyst Upgrades & Master Stock Selection - Bollywood Helpline
New COVID Pill Shows Promise Against Paxlovid in Early Head-to-Head Trial - MyChesCo
Life sciences leader behind a $900M pharma sale joins cancer firm - Stock Titan
Is Traws Pharma Inc a good long term investmentRetail Trading Trends & High Return Wealth Building - earlytimes.in
Momentum Shift: Will Traws Pharma Inc. (0T20) stock benefit from mergersMarket Sentiment Report & Real-Time Buy Zone Alerts - Улправда
Traws Pharma Begins Phase 2 Trial of Ritonavir-Free COVID-19 Treatment Ratutrelvir - MSN
How Traws Pharma Inc. stock performs during Fed tightening cyclesJuly 2025 Trade Ideas & Step-by-Step Swing Trade Plans - Улправда
How Traws Pharma Inc. stock reacts to global recession fears2025 Growth vs Value & AI Driven Stock Reports - Улправда
Why Traws Pharma Inc. (0T20) stock stays on buy lists2025 Biggest Moves & Consistent Profit Trading Strategies - DonanımHaber
Aug Momentum: How Traws Pharma Inc. stock reacts to global recession fearsWeekly Investment Recap & Free Technical Confirmation Trade Alerts - Улправда
Traws Pharma Inc (TRAW) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.24%
0.19%
자본화:
|
볼륨(24시간):